Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents

  • Salado, Irene G.
  • Zaldívar-Díez, Josefa
  • Sebastián, Víctor
  • Li, Lingling
  • Geiger, Larissa
  • González Menéndez, Silvia
  • Campillo, Nuria E.
  • Gil, Carmen
  • Morales, Aixa V.
  • Pérez, Daniel I.
  • Martínez Gil, Ana
46 p.-7 fig.-1 tab., Leucine-rich repeat kinase 2 (LRRK2) is one of the most pursued targets for Parkinson’s disease (PD) therapy. Moreover, it has recently described its role in regulating Wnt signaling and thus, it may be involved in adult neurogenesis. This new hypothesis could give rise to double disease-modifying agents firstly by the benefits of inhibiting LRRK2 and secondly by promoting adult neurogenesis. Herein we report, the design, synthesis, biological evaluation, SAR and potential binding mode of indolinelike LRRK2 inhibitors and their preliminary neurogenic effect in neural precursor cells isolated from adult mice ventricular-subventricular zone. These results open new therapeutic horizons for the use of LRRK2 inhibitors as neuroregenerative agents.Moreover, the indolinone derivatives here prepared, inhibitors of the kinase activity of LRRK2, may be considered as pharmacological probes to study the potential neuroregeneration of the damaged brain., Financial support from MINECO (grant no. SAF2012-37979-C03-01 and RTC-2015-3439-1 to A. M. and BFU2014-57494-R to A. V. M), MECD (FPU13-003262 to J. Z.D.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles

  • Nozal, Vanesa
  • Rojas-Prats, Elisa
  • Maestro, Inés
  • Gil, Carmen
  • Pérez, Daniel I.
  • Martínez Gil, Ana
14 p.-8 fig.-4 tab., Phosphodiesterase 7 (PDE7) is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP), an important cellular messenger. PDE7’s role in neurotransmission, expression profile in the brain and the druggability of other phosphodiesterases have motivated the search for potent inhibitors to treat neurodegenerative and inflammatory diseases. Different heterocyclic compounds have been described over the years; among them, phenyl-2-thioxo-(1H)-quinazolin-4-one, called S14, has shown very promising results in different in vitro and in vivo studies. Recently, polymeric nanoparticles have been used as new formulations to target specific organs and produce controlled release of certain drugs. In this work, we describe poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles loaded with S14. Their preparation, optimization, characterization and in vivo drug release profile are here presented as an effort to improve pharmacokinetic properties of this interesting PDE7 inhibitor., This research was supported by MINECO (grant RTC-2015-3439-1 and PID2019-105600RB-I00), ISCiii CIBERNED (CB18/05/00040), MECD (FPU14-00204 to E.R.-P. and FPU16-04466 to V.N.) and H2020-MSCA-ITN-2017 (grant no. 765912 to I.M.)., Peer reviewed